Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rezolute Inc

RZLT ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$4.60

▲ +0.00%

Market Cap $442.94M · Vol 201.98K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$442.94M

Small Cap

Div Yield

N/A

EPS Growth

+28.57%

YoY

RSI (14)

37.86

Momentum

Beta

0.59

vs Market

52W High

$11.44

59.79% below

52W Low

$1.08

327.91% above

Volume

201.98K

Avg 456.52K

P/B

2.39

Price-to-book

ROE

N/A

Return on equity

Free Float

89.84%

Public shares

Shariah Compliance8 STANDARDS

✗ Rezolute Inc (RZLT) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RZLT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.92%

-4.76%

+35.29%

+19.79%

YTD

+94.92%

-28.79%

+223.94%

-58.33%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-74,412,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-48.28% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	2.39
P/FCF	N/A
EPS Growth	+28.57%
Outstanding Shares	96.29M

Technical Indicators

50-Day SMA	$4.73
200-Day SMA	$4.50
RSI (14)	37.86
Beta	0.59
52-Week High	$11.44
52-Week Low	$1.08

Volume Today	201.98K
Avg Daily Volume (30D)	456.52K
Relative Volume	0.44x
Volatility (10D)	39.38
Volatility (30D)	67.88
Free Float	89.84%

Analyst Consensus

BUY

Current Price $4.60

Mean Target $9.22

52W Low$1.08 52W High$11.44

Current

Target

$1.08 $11.44

Current Analyst target

+100.48% upside potential · 10 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001XWWJC0

ISINUS76200L3096

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateSep 15, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.